# Osimertinib, platinum, and etoposide for patients with metastatic EGFR/TP53/RB1-mutant lung cancers at risk for histological transformation

Source: [science.org](https://www.science.org/doi/abs/10.1126/scitranslmed.aee6618?af=R) · 2026-11-11 · Medicine
Page: https://themorning.science/story/osimertinib-platinum-and-etoposide-for-patients-with-metastatic-egfr-tp53-rb1-mu-43fe24ad246392dc
Kind: research · Impact: medium

## In brief

- A study in Science Translational Medicine examines osimertinib combined with platinum and etoposide.
- It targets metastatic lung cancers with EGFR, TP53 and RB1 mutations that are at risk of histological transformation.
- The article was published in Volume 18, Issue 875 of the journal in November 2026.

## Why it matters

It addresses a specific high-risk group of lung cancer patients, where the tumour may change type and become harder to treat, and tests a combination therapy for them.

## Timeline

- 2026-11-11: Published in Science Translational Medicine, Volume 18, Issue 875

## Coverage

- [Osimertinib, platinum, and etoposide for patients with metastatic EGFR/TP53/RB1-mutant lung cancers at risk for histological transformation](https://www.science.org/doi/abs/10.1126/scitranslmed.aee6618?af=R) — science.org, 2026-11-11

Tags: lung cancer, osimertinib, egfr mutation, histological transformation, oncology

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science